Literature DB >> 32273582

Informative censoring - a neglected cause of bias in oncology trials.

Arnoud J Templeton1,2, Eitan Amir3, Ian F Tannock4.   

Abstract

Mesh:

Year:  2020        PMID: 32273582     DOI: 10.1038/s41571-020-0368-0

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

Review 1.  BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

Authors:  Maria Reig; Alejandro Forner; Jordi Rimola; Joana Ferrer-Fàbrega; Marta Burrel; Ángeles Garcia-Criado; Robin K Kelley; Peter R Galle; Vincenzo Mazzaferro; Riad Salem; Bruno Sangro; Amit G Singal; Arndt Vogel; Josep Fuster; Carmen Ayuso; Jordi Bruix
Journal:  J Hepatol       Date:  2021-11-19       Impact factor: 30.083

Review 2.  An urgent call to raise the bar in oncology.

Authors:  John-John B Schnog; Michael J Samson; Rijk O B Gans; Ashley J Duits
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 7.640

3.  Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study.

Authors:  Martin Roessler; Jochen Schmitt; Christoph Bobeth; Michael Gerken; Kees Kleihues-van Tol; Christoph Reissfelder; Bettina M Rau; Marius Distler; Pompiliu Piso; Christian Günster; Monika Klinkhammer-Schalke; Olaf Schoffer; Veronika Bierbaum
Journal:  BMC Cancer       Date:  2022-06-07       Impact factor: 4.638

4.  A systematic review of the quality of conduct and reporting of survival analyses of tuberculosis outcomes in Africa.

Authors:  Moses M Ngari; Susanne Schmitz; Christopher Maronga; Lazarus K Mramba; Michel Vaillant
Journal:  BMC Med Res Methodol       Date:  2021-04-27       Impact factor: 4.615

5.  Focus on Survival Analysis for Eye Research.

Authors:  Myra B McGuinness; Jessica Kasza; Zhichao Wu; Robyn H Guymer
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-05-03       Impact factor: 4.799

6.  Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Authors:  Brooke E Wilson; Alexandra Desnoyers; Michelle B Nadler; Ariadna Tibau; Eitan Amir
Journal:  Cancer Med       Date:  2021-07-28       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.